Linda-Gail Bekker stood in a sterile manufacturing plant in January 2025. For a moment, she let herself believe it.
The first HIV vaccine designed and led by African scientists might finally work.
It was a fragile hope. Fragile, because the virus doesn’t just hide. It evolves. It mutates. It laughs at our attempts to lock it down. For over forty years, HIV has been the ghost at the feast. We have treatments. We have survival. But we do not have a cure. And we certainly don’t have prevention via vaccination.
Until now?
In January 2025, the landscape shifted. Not with a bang, but with a whisper of possibility. Bekker, an infectious disease giant at the University of Cape Town, saw a path. But just as the horizon brightened, the lights went out.
The mRNA Breakthrough in HIV Research
mRNA technology saved us from Covid-19. Now, it is our best shot at cracking HIV.
Why does this matter for an HIV vaccine specifically? Because the old way of building vaccines—growing weakened viruses or proteins in labs—is too slow. Too rigid. HIV is a shape-shifter. To beat it, you need speed. You need to iterate. You need to change the script faster than the virus can change its coat.
mRNA allows exactly that. It’s code. Edit the sequence, and the body produces the protein. Days, not months.
The target is clear. The envelope protein. It’s the grappling hook HIV uses to latch onto immune cells. Block that hook, block the infection. But here is the trap: the immune system mostly sees a decoy. A flashy, mutable decoy that changes every time antibodies get close.
For decades, researchers chased these ghosts. They made vaccines that triggered responses, but never the right ones. Then, they found the holy grail: broadly neutralizing antibodies. Rare defenders. They see through the decoys. They target the hidden, conserved parts of the virus.
The problem? Your body doesn’t make them on its own. They take years of fighting a live virus to develop. A vaccine has to fake that battle. It has to guide the immune system through a choreographed dance of mutations, shot after shot, to train the body to produce these elite antibodies.
It requires precision. It requires patience.
mRNA offers the precision. And the speed.
How Political Shifts Impact HIV Vaccine Funding
The science was ready. The clinical trials were queued. Bekker’s team was poised to enroll their first participants.
Then Donald Trump returned to the White House.
On his first day, an executive order froze foreign aid. Overnight, the $45 million contract from USAID vanished. That money wasn’t just a number. It was the lifeblood of Bekker’s project. It was the fuel for years of work.
Washington had long supplied 90 percent of global HIV vaccine funding. When that tap gets turned off, the drought is immediate.
It’s a cruel twist of fate. We finally understand what immune response is needed. We finally have a tool (mRNA) that can deliver it quickly. And then, the political will evaporates.
Robert F. Kennedy Jr., overseeing health policy, adds another layer of chaos. Under his watch, the NIH began dismantling the Consortia for HIV/AIDS Vaccine Development. Grants were terminated. Support for mRNA projects was curtailed across the board.
And South Africa? The continent’s biomedical powerhouse? It found itself in Trump’s crosshairs over political accusations. Collaborative grants were halted. The bridges between US science and African expertise, built over decades, were burned.
“A perfect storm,” says Mitchell Warren of AVAC. “A storm designed to stop us from building on the most exciting science in 45 years.”
The Side Effects That Stalled mRNA Trials
But wait. It’s not just money. It’s biology.
mRNA isn’t perfect. Early trials for HIV-specific mRNA vaccines revealed a weird, persistent problem.
Chronic urticaria. Hives.
In trials by Moderna, about one in 12 patients developed hives that lasted for years. It happened across different vaccine designs. Different parts of the HIV envelope protein. But always the same side effect.
Why?
No one knows for sure. Is it the protein? The mRNA? The delivery mechanism? “No smoking gun,” says William Schief of Moderna and Scripps Research. They’ve ruled out many causes, but the connection remains murky.
It raises a question: Is HIV’s envelope protein uniquely irritating to the immune system in a way that no other vaccine antigen is?
The suspicion hangs in the air. Unanswered.
The African-Led HIV Vaccine Future
Despite the funding freeze, Bekker didn’t stop. She pivoted.
IAVI picked up the tab. But the science had to adapt. The solution? Lower doses.
The IAVI G004 trial tested the vaccine at one-tenth the dose of the original studies.
Did the hives appear?
No. At the lowest dose, the chronic urticaria never materialized.
The immune response? Still potent. Still capable of triggering the antibodies they need.
Now, the team is hunting for the sweet spot. Enough dose to train the immune system. Not enough to trigger the skin reaction. A balance, struck carefully in South Africa, away from the defunded US pipeline.
Bekker is still pushing. Philanthropies and other governments are stepping in to fill the black hole left by US withdrawal. Trials are moving, albeit scaled down.
“We know what we need to do,” says Barton Haynes of Duke.
The science is solid. The technology is proven. The political headwinds are gale-force.
Can we beat HIV without US funding? Without the biggest laboratory of the West?
Maybe not. But Bekker is still inside that manufacturing plant. And she hasn’t turned off the lights.
The virus is still mutating. The window is still open. And for now, the Africans are driving the bus.
